Treatment satisfaction in multiple sclerosis
Disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) are associated with inconvenient methods of administration, significant side effects, and low adherence rates. This study was undertaken to compare treatment satisfaction in MS patients treated with interferon beta-1a in...
Uložené v:
| Vydané v: | International journal of MS care Ročník 16; číslo 2; s. 68 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
2014
|
| ISSN: | 1537-2073 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) are associated with inconvenient methods of administration, significant side effects, and low adherence rates. This study was undertaken to compare treatment satisfaction in MS patients treated with interferon beta-1a intramuscular (IFNβ-1a IM), interferon beta-1a subcutaneous (IFNβ-1a SC), glatiramer acetate (GA), and natalizumab (NTZ), and to examine the associations between treatment satisfaction ratings and adherence to therapy.
Two hundred twenty-six treated MS patients completed the Treatment Satisfaction Questionnaire for Medicine. Multivariable models were used to compare treatment satisfaction across groups.
There were no statistically significant differences in overall treatment satisfaction. The NTZ group reported greater satisfaction with the ability of the medication to treat or prevent MS than the IFNβ-1a IM group. The NTZ group also reported higher overall convenience scores than the IFNβ-1a IM group and greater satisfaction with ease of use of the medication than the interferon and GA groups. Patients in the IFNβ-1a IM group reported less satisfaction with ease of planning when to use the medication than those in the other groups. Convenience was associated with adherence in IFNβ-1a SC- and GA-treated patients, with lower convenience scores associated with lower adherence.
These results may be useful to MS patients and health-care providers facing decisions about DMT use. |
|---|---|
| AbstractList | Disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) are associated with inconvenient methods of administration, significant side effects, and low adherence rates. This study was undertaken to compare treatment satisfaction in MS patients treated with interferon beta-1a intramuscular (IFNβ-1a IM), interferon beta-1a subcutaneous (IFNβ-1a SC), glatiramer acetate (GA), and natalizumab (NTZ), and to examine the associations between treatment satisfaction ratings and adherence to therapy.BACKGROUNDDisease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) are associated with inconvenient methods of administration, significant side effects, and low adherence rates. This study was undertaken to compare treatment satisfaction in MS patients treated with interferon beta-1a intramuscular (IFNβ-1a IM), interferon beta-1a subcutaneous (IFNβ-1a SC), glatiramer acetate (GA), and natalizumab (NTZ), and to examine the associations between treatment satisfaction ratings and adherence to therapy.Two hundred twenty-six treated MS patients completed the Treatment Satisfaction Questionnaire for Medicine. Multivariable models were used to compare treatment satisfaction across groups.METHODSTwo hundred twenty-six treated MS patients completed the Treatment Satisfaction Questionnaire for Medicine. Multivariable models were used to compare treatment satisfaction across groups.There were no statistically significant differences in overall treatment satisfaction. The NTZ group reported greater satisfaction with the ability of the medication to treat or prevent MS than the IFNβ-1a IM group. The NTZ group also reported higher overall convenience scores than the IFNβ-1a IM group and greater satisfaction with ease of use of the medication than the interferon and GA groups. Patients in the IFNβ-1a IM group reported less satisfaction with ease of planning when to use the medication than those in the other groups. Convenience was associated with adherence in IFNβ-1a SC- and GA-treated patients, with lower convenience scores associated with lower adherence.RESULTSThere were no statistically significant differences in overall treatment satisfaction. The NTZ group reported greater satisfaction with the ability of the medication to treat or prevent MS than the IFNβ-1a IM group. The NTZ group also reported higher overall convenience scores than the IFNβ-1a IM group and greater satisfaction with ease of use of the medication than the interferon and GA groups. Patients in the IFNβ-1a IM group reported less satisfaction with ease of planning when to use the medication than those in the other groups. Convenience was associated with adherence in IFNβ-1a SC- and GA-treated patients, with lower convenience scores associated with lower adherence.These results may be useful to MS patients and health-care providers facing decisions about DMT use.CONCLUSIONSThese results may be useful to MS patients and health-care providers facing decisions about DMT use. Disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) are associated with inconvenient methods of administration, significant side effects, and low adherence rates. This study was undertaken to compare treatment satisfaction in MS patients treated with interferon beta-1a intramuscular (IFNβ-1a IM), interferon beta-1a subcutaneous (IFNβ-1a SC), glatiramer acetate (GA), and natalizumab (NTZ), and to examine the associations between treatment satisfaction ratings and adherence to therapy. Two hundred twenty-six treated MS patients completed the Treatment Satisfaction Questionnaire for Medicine. Multivariable models were used to compare treatment satisfaction across groups. There were no statistically significant differences in overall treatment satisfaction. The NTZ group reported greater satisfaction with the ability of the medication to treat or prevent MS than the IFNβ-1a IM group. The NTZ group also reported higher overall convenience scores than the IFNβ-1a IM group and greater satisfaction with ease of use of the medication than the interferon and GA groups. Patients in the IFNβ-1a IM group reported less satisfaction with ease of planning when to use the medication than those in the other groups. Convenience was associated with adherence in IFNβ-1a SC- and GA-treated patients, with lower convenience scores associated with lower adherence. These results may be useful to MS patients and health-care providers facing decisions about DMT use. |
| Author | Glanz, Bonnie I Healy, Brian C Musallam, Alexander Weiner, Howard L Rintell, David J Chitnis, Tanuja |
| Author_xml | – sequence: 1 givenname: Bonnie I surname: Glanz fullname: Glanz, Bonnie I organization: Department of Neurology, Harvard Medical School, Boston, MA, USA (BIG, DJR, TC, HLW, BCH); Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA (BIG, AM, DJR, TC, HLW, BCH); and Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA (BCH) – sequence: 2 givenname: Alexander surname: Musallam fullname: Musallam, Alexander organization: Department of Neurology, Harvard Medical School, Boston, MA, USA (BIG, DJR, TC, HLW, BCH); Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA (BIG, AM, DJR, TC, HLW, BCH); and Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA (BCH) – sequence: 3 givenname: David J surname: Rintell fullname: Rintell, David J organization: Department of Neurology, Harvard Medical School, Boston, MA, USA (BIG, DJR, TC, HLW, BCH); Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA (BIG, AM, DJR, TC, HLW, BCH); and Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA (BCH) – sequence: 4 givenname: Tanuja surname: Chitnis fullname: Chitnis, Tanuja organization: Department of Neurology, Harvard Medical School, Boston, MA, USA (BIG, DJR, TC, HLW, BCH); Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA (BIG, AM, DJR, TC, HLW, BCH); and Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA (BCH) – sequence: 5 givenname: Howard L surname: Weiner fullname: Weiner, Howard L organization: Department of Neurology, Harvard Medical School, Boston, MA, USA (BIG, DJR, TC, HLW, BCH); Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA (BIG, AM, DJR, TC, HLW, BCH); and Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA (BCH) – sequence: 6 givenname: Brian C surname: Healy fullname: Healy, Brian C organization: Department of Neurology, Harvard Medical School, Boston, MA, USA (BIG, DJR, TC, HLW, BCH); Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA (BIG, AM, DJR, TC, HLW, BCH); and Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA (BCH) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25061430$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9j0tLxDAUhbMYcR76B1xIly7smNy86lIGR4UBN-O63OYBkTStTbrw3zvg6OrA4ePjnDVZpCE5Qm4Y3WoA8cAk1zVQzbdAGa8psAVZ_ZdLss75k1IumeaXZAmSKiY4XZH74-Sw9C6VKmMJ2aMpYUhVSFU_xxLG6KpsopuGHPIVufAYs7s-54Z87J-Pu9f68P7ytns61IYzzWqkAgyCFZ5Z2zUGbKdcI6zkyijsToOYbBAcRS-5FNraR4HS-kZzjuA72JC7X-84DV-zy6XtQzYuRkxumHPLpGgU16DoCb09o3PXO9uOU-hx-m7_HsIP_nxSRQ |
| CitedBy_id | crossref_primary_10_3389_fneur_2024_1379712 crossref_primary_10_1371_journal_pone_0185766 crossref_primary_10_1097_PHM_0000000000001869 crossref_primary_10_1177_1352458519881558 crossref_primary_10_1016_j_msard_2017_10_002 crossref_primary_10_1016_j_msard_2019_04_036 crossref_primary_10_1007_s40120_023_00497_2 crossref_primary_10_1016_j_msard_2020_102413 crossref_primary_10_1177_1756286421998902 crossref_primary_10_7224_1537_2073_2017_031 crossref_primary_10_1016_j_msard_2016_12_002 crossref_primary_10_3389_fneur_2021_637615 crossref_primary_10_1002_acn3_51410 crossref_primary_10_2147_PPA_S291485 crossref_primary_10_1016_j_clinthera_2020_03_005 crossref_primary_10_1177_20552173241251707 crossref_primary_10_1016_j_msard_2018_11_016 crossref_primary_10_2147_PPA_S509525 crossref_primary_10_36469_001c_123336 crossref_primary_10_1016_j_dhjo_2019_05_005 crossref_primary_10_1177_1352458520932776 crossref_primary_10_2147_PPA_S254427 crossref_primary_10_1177_13524585251330085 crossref_primary_10_1007_s10865_017_9900_9 crossref_primary_10_1177_1352458516676643 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.7224/1537-2073.2013-021 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 25061430 |
| Genre | Journal Article |
| GroupedDBID | 2QV 2WC 53G AAWTL ACGFO ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL DIK E3Z EBS EIHBH EJD FRP GX1 HYE NPM OK1 RPM TR2 Y3D 7X8 |
| ID | FETCH-LOGICAL-c3171-a042ca2d4f1ddb8c2db6e84d536c6ab207158a2e0af53547dd94a5df8733a2fb2 |
| IEDL.DBID | 7X8 |
| ISSN | 1537-2073 |
| IngestDate | Sun Nov 09 09:05:17 EST 2025 Thu Jan 02 22:16:42 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3171-a042ca2d4f1ddb8c2db6e84d536c6ab207158a2e0af53547dd94a5df8733a2fb2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://doi.org/10.7224/1537-2073.2013-021 |
| PMID | 25061430 |
| PQID | 1548637260 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1548637260 pubmed_primary_25061430 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-00-00 |
| PublicationDateYYYYMMDD | 2014-01-01 |
| PublicationDate_xml | – year: 2014 text: 2014-00-00 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | International journal of MS care |
| PublicationTitleAlternate | Int J MS Care |
| PublicationYear | 2014 |
| References | 17967842 - Mult Scler. 2007 Nov;13(9):1146-52 22992073 - N Engl J Med. 2012 Sep 20;367(12):1098-107 14987333 - Health Qual Life Outcomes. 2004 Feb 26;2:12 23303882 - Mult Scler. 2013 Jan;19(1):29-30 15957512 - Mult Scler. 2005 Jun;11(3):306-9 16283615 - Ann Neurol. 2005 Dec;58(6):840-6 17027888 - Autoimmun Rev. 2006 Oct;5(8):532-6 9521260 - Neurology. 1998 Mar;50(3):701-8 18057899 - Eur Neurol. 2008;59(3-4):131-5 19921303 - J Neurol. 2010 Apr;257(4):584-9 21078142 - Health Qual Life Outcomes. 2010 Nov 15;8:133 23303881 - Mult Scler. 2013 Jan;19(1):26-8 8469318 - Neurology. 1993 Apr;43(4):655-61 20561039 - Eur J Neurol. 2011 Jan;18(1):69-77 22992072 - N Engl J Med. 2012 Sep 20;367(12):1087-97 16510744 - N Engl J Med. 2006 Mar 2;354(9):899-910 9820297 - Lancet. 1998 Nov 7;352(9139):1498-504 20089952 - N Engl J Med. 2010 Feb 4;362(5):387-401 6685237 - Neurology. 1983 Nov;33(11):1444-52 21991951 - N Engl J Med. 2011 Oct 6;365(14):1293-303 8602746 - Ann Neurol. 1996 Mar;39(3):285-94 15947079 - N Engl J Med. 2005 Jul 28;353(4):369-74 19300966 - J Neurol. 2008 Dec;255 Suppl 6:87-92 7617181 - Neurology. 1995 Jul;45(7):1268-76 17559722 - Curr Med Res Opin. 2007 Jun;23(6):1209-15 |
| References_xml | – reference: 23303882 - Mult Scler. 2013 Jan;19(1):29-30 – reference: 22992072 - N Engl J Med. 2012 Sep 20;367(12):1087-97 – reference: 7617181 - Neurology. 1995 Jul;45(7):1268-76 – reference: 16283615 - Ann Neurol. 2005 Dec;58(6):840-6 – reference: 9820297 - Lancet. 1998 Nov 7;352(9139):1498-504 – reference: 6685237 - Neurology. 1983 Nov;33(11):1444-52 – reference: 8469318 - Neurology. 1993 Apr;43(4):655-61 – reference: 17559722 - Curr Med Res Opin. 2007 Jun;23(6):1209-15 – reference: 15947079 - N Engl J Med. 2005 Jul 28;353(4):369-74 – reference: 16510744 - N Engl J Med. 2006 Mar 2;354(9):899-910 – reference: 8602746 - Ann Neurol. 1996 Mar;39(3):285-94 – reference: 20089952 - N Engl J Med. 2010 Feb 4;362(5):387-401 – reference: 19921303 - J Neurol. 2010 Apr;257(4):584-9 – reference: 17027888 - Autoimmun Rev. 2006 Oct;5(8):532-6 – reference: 14987333 - Health Qual Life Outcomes. 2004 Feb 26;2:12 – reference: 23303881 - Mult Scler. 2013 Jan;19(1):26-8 – reference: 22992073 - N Engl J Med. 2012 Sep 20;367(12):1098-107 – reference: 19300966 - J Neurol. 2008 Dec;255 Suppl 6:87-92 – reference: 18057899 - Eur Neurol. 2008;59(3-4):131-5 – reference: 21991951 - N Engl J Med. 2011 Oct 6;365(14):1293-303 – reference: 21078142 - Health Qual Life Outcomes. 2010 Nov 15;8:133 – reference: 15957512 - Mult Scler. 2005 Jun;11(3):306-9 – reference: 20561039 - Eur J Neurol. 2011 Jan;18(1):69-77 – reference: 9521260 - Neurology. 1998 Mar;50(3):701-8 – reference: 17967842 - Mult Scler. 2007 Nov;13(9):1146-52 |
| SSID | ssj0035173 |
| Score | 2.0945625 |
| Snippet | Disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) are associated with inconvenient methods of administration, significant side... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 68 |
| Title | Treatment satisfaction in multiple sclerosis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25061430 https://www.proquest.com/docview/1548637260 |
| Volume | 16 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFH6oFfHivtSNCB4d2sySSU8iYvFgSw8Vegsvs0AvaWvQ3--bLNWLIHjJYWAg89Yv73uTB3AnlY49RT1mScFMokWGyJHlPueIUg1SrKaWvOrxOJ3NBpOm4FY2bZVtTKwCtV2YUCPvBWidCE3w-2G5YmFqVGBXmxEam9ARBGWCVevZmkUQqmaYyak1WYMW9aUZTVmrt14L3V2ByYx_h5hVqhnu__clD2CvAZnRY20Vh7DhiiPYGTU0-jHcT9v28qj8cbshmhdR22AYlbSTMui8PIG34fP06YU1YxOYITAQMyQ_NMit9LG1eWq4zROXSlJGYhLM6dCxSpG7PnollNTWDiQq61MtBHLS0SlsFYvCnUPkkfCNyXUutJCImnzUck9fGU4aJ63uwm0rh4zMMnANWLjFR5l9S6ILZ7Uws2X9_4yMUBeBAtG_-MPuS9glBcm66HEFHU9O6a5h23ySdN5vKn3TczwZfQFdQbPg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+satisfaction+in+multiple+sclerosis&rft.jtitle=International+journal+of+MS+care&rft.au=Glanz%2C+Bonnie+I&rft.au=Musallam%2C+Alexander&rft.au=Rintell%2C+David+J&rft.au=Chitnis%2C+Tanuja&rft.date=2014-01-01&rft.issn=1537-2073&rft.volume=16&rft.issue=2&rft.spage=68&rft_id=info:doi/10.7224%2F1537-2073.2013-021&rft_id=info%3Apmid%2F25061430&rft_id=info%3Apmid%2F25061430&rft.externalDocID=25061430 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-2073&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-2073&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-2073&client=summon |